XTANDI (enzalutamide): A New Treatment for Metastatic Castration-Resistant Prostate Cancer
نویسنده
چکیده
Hormonal therapies act to inhibit the actions of androgens (testosterone and dihydrotestosterone [DHT]), which drive prostate cancer growth. Men whose prostate cancer returns following initial treatments with surgery or radiation are usually treated with therapies to lower their androgen levels (ADT), such as Lupron, Eligard, Zoladex, Trelstar, Vantas, Firmagon or surgical removal of the testicles. Despite these treatments, prostate cancer sometimes returns. This state is referred to as castration-resistant prostate cancer, or CRPC.
منابع مشابه
Enzalutamide for patients with metastatic castration-resistant prostate cancer
OBJECTIVE To review and evaluate current literature on the US Food and Drug Administration (FDA)-approved drug enzalutamide (XTANDI(®)) in metastatic castration-resistant prostate cancer. DATA SOURCES Literature search was done through PubMed using the terms enzalutamide, MDV3100, abiraterone, and castration-resistant prostate cancer. Data from FDA product labels were also used. STUDY SELEC...
متن کاملRadium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
© 2015 Harborside Press® In the United States, prostate cancer is the most common cancer and second leading cause of cancer-related deaths in men. It is estimated that 220,800 new cases of prostate cancer will have been diagnosed in 2015, with an estimated 27,540 deaths (American Cancer Society, 2015). Although prostate cancer is typically diagnosed when it is localized and considered curable, ...
متن کاملA Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملA Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملNavigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives.
BACKGROUND Treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved rapidly. In particular, five new treatments that extend survival in mCRPC have been approved since 2010, including the chemotherapy cabazitaxel (Jevtana®), hormonal agents abiraterone (Zytiga®) and enzalutamide (Xtandi®), vaccine sipuleucel-T (Provenge®), and radiopharmaceutical radium-223 (Xofigo®); all...
متن کامل